当前位置: 首页 >> 检索结果
362. Impact of the COVID-19 Pandemic on Antibiotic Resistant Infection Burden in U.S. Hospitals : Retrospective Cohort Study of Trends and Risk Factors.
作者: Christina Yek.;Alex G Mancera.;Guoqing Diao.;Morgan Walker.;Maniraj Neupane.;Emad A Chishti.;Roxana Amirahmadi.;Mary E Richert.;Chanu Rhee.;Michael Klompas.;Bruce Swihart.;Sarah R Warner.;Sameer S Kadri.; .
来源: Ann Intern Med. 2025年178卷6期796-807页
In 2022, the U.S. Centers for Disease Control and Prevention reported increases in antimicrobial resistance (AMR) across U.S. hospitals during the COVID-19 pandemic. The key drivers and lasting effects of this phenomenon remain unexplored.
364. Sexual Trauma, Suicide, and Overdose in a National Cohort of Older Veterans.
作者: Anita S Hargrave.;Beth E Cohen.;Carolyn J Gibson.;Salomeh Keyhani.;Yixia Li.;W John Boscardin.;Amy L Byers.
来源: Ann Intern Med. 2025年178卷6期775-787页
Little is known about the association between military sexual trauma (MST) and risk for suicide-related outcomes later in life.
365. High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302).
作者: Sharon A Riddler.;Zoe Moodie.;Jesse Clark.;Catherine Yen.;Mary Allen.;Briana D Furch.;Huiyin Lu.;Shannon Grant.;Kajari Mondal.;Maija Anderson.;Janine Maenza.;Maria P Lemos.;Amanda S Woodward Davis.;Stephen R Walsh.;Magdalena E Sobieszczyk.;Ian Frank.;Paul Goepfert.;Kathryn E Stephenson.;Lindsey R Baden.;Hong-Van Tieu.;Michael C Keefer.;M Juliana McElrath.;James G Kublin.;Lawrence Corey.
来源: Ann Intern Med. 2025年178卷7期963-974页
The mRNA platform is under investigation for many vaccines, including HIV-1 vaccines.
369. Availability of Cardioprotective Medications for Type 2 Diabetes in the Medicaid Program.
作者: Anil N Makam.;Logan Bailey.;Nigel Anderson.;Kathy Bellitti.;Sasha Skinner.;Oanh Kieu Nguyen.
来源: Ann Intern Med. 2025年178卷6期808-818页
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are the only type 2 diabetes medications that reduce cardiovascular disease and death, yet their availability in Medicaid is unclear.
370. Risk for Stroke After Newly Diagnosed Atrial Fibrillation During Hospitalization for Other Primary Diagnoses : A Retrospective Cohort Study.
作者: Husam Abdel-Qadir.;Madison Gunn.;Jiming Fang.;Tomi Odugbemi.;Irene Jeong.;Peter C Austin.;Paul Dorian.;Cynthia A Jackevicius.;Douglas S Lee.;Sheldon M Singh.;Karen Tu.;Dennis T Ko.
来源: Ann Intern Med. 2025年178卷6期765-774页
Atrial fibrillation (AF) that is first diagnosed during hospitalization for other causes can subside with resolution of the inciting stressor.
371. The Rise of Psilocybin Use in the United States: A Multisource Observational Study.
作者: Karilynn M Rockhill.;Joshua C Black.;Michael S Ladka.;Kanku B Sumbundu.;Heather A Olsen.;Jennifer S Jewell.;Joshua Hunt.;R Cameron Wolf.;Karuna Nerurkar.;Richard C Dart.;Andrew A Monte.
来源: Ann Intern Med. 2025年178卷7期1052-1054页 372. Prophylactic Weekly Efanesoctocog Alfa Versus Standard-Care Factor VIII in People Living With Severe Hemophilia A : A Cost-Effectiveness Analysis.
作者: Satoko Ito.;Kunal C Potnis.;Jessica Preston Harvey.;Manraj Sra.;Jan Phillipp Bewersdorf.;Robert D Bona.;Harlan M Krumholz.;Adam Cuker.;Ankur Pandya.;George Goshua.
来源: Ann Intern Med. 2025年178卷6期819-828页
Prophylaxis goals for patients with severe hemophilia A encompass advancement toward the hemophilia-free mind (freedom from bleeding, pain, arthropathy, and treatment burden). Efanesoctocog alfa, the first ultra-long half-life factor VIII agent that enables once-weekly prophylaxis, shows a 77% improvement in annualized bleeding rate compared with standard-care factor VIII prophylaxis.
|